zocilurtatug pelitecan (ZL-1310)
Small Cell Lung Cancer (2L extensive-stage)
Phase 3Global Phase 3 study launched Oct 2025
Key Facts
Indication
Small Cell Lung Cancer (2L extensive-stage)
Phase
Phase 3
Status
Global Phase 3 study launched Oct 2025
Company
About Zai Lab
Founded in 2014 by Dr. Samantha Du, Zai Lab has grown into a leading global biopharma with a dual headquarters in China and the U.S. The company combines in-licensed assets with strategic partnerships and internal R&D to build a robust pipeline, with eight products already on the market in China. Its mission is to bridge gaps in global health by advancing breakthrough therapies for patients with significant unmet medical needs.
View full company profile